Impact News +++ Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference (GlobeNewswire EN) +++ ANAVEX Aktie -3,83%

JAZZ PHARMACEUTICALS Aktie

>JAZZ PHARMA Aktienkurs

153.2 EUR +4.0% (TradegateBSX)

Ask: 155.4 EUR / 40 Stück

Bid: 153.9 EUR / 40 Stück

Tagesumsatz: 170 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

JAZZ PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>JAZZ PHARMA Performance

1 Woche: +4,2%

1 Monat: +1,5%

3 Monate: -6,3%

6 Monate: +38,8%

1 Jahr: +11,7%

laufendes Jahr: +1,2%

>JAZZ PHARMACEUTICALS Aktie

Name:

JAZZ PHARMACEUTICALS

Land:

Irland

Sektor:

Gesundheit

ISIN/ Wkn:

IE00B4Q5ZN47 / A1JS1K

Symbol/ Ticker:

J7Z (Frankfurt) / JAZZ (NASDAQ)

Kürzel:

FRA:J7Z, ETR:J7Z, J7Z:GR, NASDAQ:JAZZ

Index:

Webseite:

http://www.jazzpharma.com..

Profil:

Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to resear..
>Volltext..

Marktkapitalisierung:

8941.63 Mio. EUR

Unternehmenswert:

11826.92 Mio. EUR

Umsatz:

3531.47 Mio. EUR

EBITDA:

1019.99 Mio. EUR

Nettogewinn:

-312.97 Mio. EUR

Gewinn je Aktie:

-5.06 EUR

Schulden:

4610.74 Mio. EUR

Liquide Mittel:

1049.86 Mio. EUR

Operativer Cashflow:

1182.16 Mio. EUR

Bargeldquote:

0.9

Umsatzwachstum:

-1.19%

Gewinnwachstum:

-175.49%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

JAZZ PHARMACEUTICALS, JAZZ PHARMA

Letzte Datenerhebung:

25.02.26

>JAZZ PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 60.77 Mio. St.

Frei handelbar: 94.69%

Leerverk. Aktien: 9.32%

Rückkaufquote: 0.88%

Mitarbeiter: 2800

Umsatz/Mitarb.: 1.23 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 22.77%

Bewertung:

KGV: -

KGV lG: 21.91

KUV: 2.44

KBV: 2.75

PEG-Ratio: -

EV/EBITDA: 11.6

Rentabilität:

Bruttomarge: 73.01%

Gewinnmarge: -8.86%

Operative Marge: 12.39%

Managementeffizenz:

Gesamtkaprendite: -3.12%

Eigenkaprendite: -9.06%

>JAZZ PHARMA Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>JAZZ PHARMA Chart & Kurs - NASDAQ

>JAZZ PHARMA News

25.02.26 - 11:48	(3⁺) Chart Tracker: Circle, Jazz Pharma (Stock3)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.26 - 03:15	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks)
	Jazz (JAZZ) delivered earnings and revenue surprises of +0.27% and +1.56%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

24.02.26 - 22:42	Jazz Pharmaceuticals Plc Q4 Profit Climbs (AFX)
	WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million, or $3.......

24.02.26 - 22:18	Jazz Pharmaceuticals GAAP EPS of $6.64 beats by $3.75, revenue of $1.2B beats by $30M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.02.26 - 22:09	Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance (PR Newswire)
	– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – – Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA – – Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 – – Epidiolex® achieved $1.1......

17.02.26 - 22:18	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
	DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 Fireside chat at 7:30 a.m. PT / 10:30 a.m. ET / 2:30......

17.02.26 - 17:30	Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
	Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

11.02.26 - 16:00	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
	Investors need to pay close attention to Jazz Pharmaceuticals stock based on the movements in the options market lately....

10.02.26 - 22:18	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
	DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.......

08.01.26 - 22:06	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer (PR Newswire)
	Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga......

07.01.26 - 19:36	Jazz Pharmaceuticals′ Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial (Benzinga)
	Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years. read more...

07.01.26 - 07:42	Jazz Pharma Reports Positive Phase 3 HERIZON-GEA-01 Results (AFX)
	WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, wit......

06.01.26 - 22:24	Jazz Pharmaceuticals: Aktie gibt nach gemischten Phase-3-Studiendaten nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.12.25 - 22:21	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
	DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 The Company will host an investor webcast on Friday,......

17.12.25 - 22:18	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
	DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 The Company will host an investor webcast on Friday,......

12.12.25 - 02:01	Insiderhandel: SVP, Technical Operations verkauft Aktien von Jazz Pharmaceuticals im Wert von 379366 USD (Insiderkauf)
	Henderson, Mary Elizabeth - Vorstand - Tag der Transaktion: 2025-12-09...

10.12.25 - 00:01	Insiderhandel: SVP, Chief Accounting Officer verkauft Aktien von Jazz Pharmaceuticals im Wert von 797783 USD (Insiderkauf)
	Carr, Patricia - Vorstand - Tag der Transaktion: 2025-12-05...

05.12.25 - 15:03	Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting (PR Newswire)
	New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the......

02.12.25 - 22:06	Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
	Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data For U.S. media and investors only DUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz......

02.12.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Jazz Pharmaceuticals im Wert von 13780337 USD (Insiderkauf)
	Cozadd, Bruce C. - Aufsichtsrat - Tag der Transaktion: 2025-11-26...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Verstohlene Geschenke nimmt der Gottlose an, den Gang des Rechtes zu beugen. - Altes Testament: Spruch

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram